Valbiotis SA (ALVAL) Price & Analysis

Compare

5 Followers

ALVAL Stock Chart & Stats

€0.72

€0.05(3.27%)

At close: Jan 09 4:00 PM EST

€0.72

€0.05(3.27%)

Day’s Range― - ―

52-Week Range€0.54 - €1.35

Previous CloseN/A

Volume46.53K

Average Volume (3M)112.19K

Market Cap

€25.20M

Enterprise Value€19.31M

Total Cash (Recent Filing)€11.58M

Total Debt (Recent Filing)€5.72M

Price to Earnings (P/E)―

Beta0.92

Next Earnings

Mar 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding23,698,235

10 Day Avg. Volume162,174

30 Day Avg. Volume112,190

Financial Highlights & Ratios

PEG Ratio-0.35

Price to Book (P/B)2.32

Price to Sales (P/S)137.18

P/FCF Ratio-2.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Scientific R&D FocusValbiotis' emphasis on scientifically substantiated nutritional solutions and clinical evaluation builds a durable competitive advantage. Clinical data and formulation know-how increase credibility with healthcare professionals and partners, raising barriers to entry and supporting long-term commercial adoption.

Prevention Market PositioningThe company's clear focus on prevention and health maintenance targets chronic metabolic and cardiovascular areas with ongoing, recurring demand. This positioning supports sustainable product demand and recurring revenue potential if clinical efficacy is validated and consumer trust is maintained over the medium term.

Relatively Stable Balance SheetReported manageable leverage and a healthy equity share of assets give Valbiotis greater financial flexibility than highly indebted peers. This relative balance-sheet resilience can extend runway for clinical work and commercialization, reducing short-term refinancing pressure while strategy execution continues.

Bears Say

Persistent Negative MarginsSustained negative gross and net margins, including a negative gross profit in 2024, point to structural profitability issues. Long-term inability to generate positive margins will force continued external funding, constrain reinvestment in R&D and commercialization, and raise dilution risk for shareholders.

Declining And Inconsistent RevenueThe company's inconsistent top-line and a marked revenue decline in 2024 undermine scaling prospects and weaken commercial validation. Persistent revenue volatility complicates forecasting, reduces bargaining power with distributors or partners, and raises execution risk for long-term growth plans.

Worsening Cash Flow And Funding RelianceConsistent negative operating and free cash flow, worsening in 2024, indicates reliance on external financing to fund operations. Continued FCF deterioration and rising net debt erode financial flexibility, heighten refinancing and dilution risk, and could constrain strategic investments if markets tighten.

Valbiotis SA News

Valbiotis SA’s TOTUM-448 Trial: A Potential Game-Changer for Liver Health

Valbiotis SA (($DE:8JD)) announced an update on their ongoing clinical study. Study Overview: Valbiotis SA is conducting a...

4M ago

8JD

Valbiotis Announces Monthly Voting Rights and Share Capital Update

Valbiotis SA ( ($FR:ALVAL) ) has shared an update. Valbiotis has announced its monthly information on the total...

11M ago

Valbiotis Introduces Lipidrive as a Safe Alternative to Red Yeast Rice

Valbiotis SA ( ($FR:ALVAL) ) has shared an announcement. Valbiotis has introduced Lipidrive, a scientifically proven alternative to...

11M ago

Valbiotis SA Confirms Strategic Growth and Successful Product Launch

Valbiotis SA ( ($FR:ALVAL) ) just unveiled an update. Valbiotis SA has transitioned from an R&D-focused company to...

12M ago

Valbiotis Releases Monthly Voting Rights and Share Capital Data

The latest announcement is out from Valbiotis SA ( ($FR:ALVAL) ). Valbiotis announced its monthly voting rights and...

12M ago

Valbiotis Releases Monthly Voting Rights and Shares Update

An announcement from Valbiotis SA ( ($FR:ALVAL) ) is now available. Valbiotis has disclosed its monthly update on...

1y ago

Valbiotis Launches Innovative Metabolic Health Supplement in France

Valbiotis SA ( ($FR:ALVAL) ) just unveiled an announcement. Valbiotis announced the launch of its dietary supplement, Valbiotis®PRO...

1y ago

Valbiotis Sets Ambitious 2030 Growth Targets with Focus on Natural Health Supplements

Valbiotis SA ( ($FR:ALVAL) ) has shared an announcement. Valbiotis has announced its strategic and financial objectives for...

1y ago

Valbiotis Achieves Clinical Success with Lipidrive® for Cholesterol Management

Valbiotis SA ( ($FR:ALVAL) ) has issued an update. Valbiotis has announced the successful results of its Phase...

1y ago

Valbiotis Reports Half-Year Liquidity Contract Update

Valbiotis SA ( ($FR:ALVAL) ) just unveiled an announcement. Valbiotis has released its half-year liquidity contract report showing...

1y ago

ALVAL FAQ

What was Valbiotis SA’s price range in the past 12 months?

Valbiotis SA lowest stock price was €0.54 and its highest was €1.35 in the past 12 months.

What is Valbiotis SA’s market cap?

Valbiotis SA’s market cap is €25.20M.

When is Valbiotis SA’s upcoming earnings report date?

Valbiotis SA’s upcoming earnings report date is Mar 18, 2026 which is in 29 days.

How were Valbiotis SA’s earnings last quarter?

Valbiotis SA released its earnings results on Oct 09, 2025. The company reported -€0.194 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.194.

Is Valbiotis SA overvalued?

According to Wall Street analysts Valbiotis SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Valbiotis SA pay dividends?

Valbiotis SA does not currently pay dividends.

What is Valbiotis SA’s EPS estimate?

Valbiotis SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Valbiotis SA have?

Valbiotis SA has 23,698,235 shares outstanding.

What happened to Valbiotis SA’s price movement after its last earnings report?

Valbiotis SA reported an EPS of -€0.194 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.599%.

Which hedge fund is a major shareholder of Valbiotis SA?

Currently, no hedge funds are holding shares in FR:ALVAL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Valbiotis SA

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.